SetPoint Medical announced today that the FDA approved its SetPoint neuroimmune modulation system for treating rheumatoid ...

The FDA has approved the SetPoint System, a vagus nerve stimulator from SetPoint Medical, for the treatment of rheumatoid ...

The agency’s decision was based on the outcomes of the double-blind, randomised, sham-controlled RESET-RA study.

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...

A first-of-its-kind implant has just been granted approval from the US Food and Drug Administration (FDA) for the treatment ...

The device stimulates the vagus nerve, signaling the body to tamp down the inflammation that contributes to the disease.

The SetPoint System consists of a neurostimulation device that is surgically placed under general anesthesia on the vagus nerve.

The Food and Drug Administration has approved a vagus nerve bioimplant to treat rheumatoid arthritis (RA). The scientific ...

SetPoint Medical has been given an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) greenlighting it to begin a clinical trial to test its modulation platform ...

SetPoint Medical appointed Murthy Simhambhatla, PhD as President and Chief Executive Officer. He brings med device, diagnostics, biopharma experience.

SetPoint Medical's vagus nerve stimulator has received FDA approval for treating moderate-to-severe rheumatoid arthritis (RA) ...

The FDA has approved a medical device that stimulates the vagus nerve for the treatment of moderate-to-severe rheumatoid ...